Filter By Industry
Filter By Tag

Newsroom

Castle Biosciences, Inc. Press releases

1 - 4 of 4 Press Releases

Castle Biosciences exclusively licenses mesothelioma test technology; Availability on track for 4Q
Sep 12, 2012
Company is completing DecisionDx-Mesothelioma validation under CAP accredited / CLIA certified standard operating procedures; Company present and information being presented at this week’s International Mesothelioma Interest Group (IMIG) meeting

Castle Biosciences Announces Clinical Availability of the DecisionDx-Thymoma Test
Jun 04, 2012
Data presented this weekend at the American Society of Clinical Oncology 2012 Annual Meeting shows the DecisionDx-Thymoma test to be superior to traditional histopathology in predicting the risk of metastasis of thymoma tumors

Castle Biosciences licenses thymoma test technology; Availability on track for end of 1Q 2012
Jan 24, 2012
DecisionDx-Thymoma test is intended to significantly improve metastatic risk staging when paired with traditional histopathology in thymoma tumors

Castle Biosciences licenses use of gene to detect metastasis in uveal and cutaneous melanoma
Oct 21, 2011
Further validation is needed, but studies indicate that the BAP1 gene predicts metastasis of ocular melanoma tumors


Castle Biosciences, Inc. RSS Feed